We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 2.54% | 323.00 | 316.00 | 330.00 | 323.00 | 315.00 | 315.00 | 42,231 | 14:54:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.81 | 409.88M |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
MaxCyte Inc. (MXCT.LN) said Friday that its signed an agreement with Gilead Sciences Inc. (GILD) company Kite to help it develop CAR-T cancer therapies.
Life-sciences company MaxCyte said it will provide Kite with technology to help it engineer nonviral cells to develop CAR-T drug candidates. In return, MaxCyte is eligible to receive development and approval milestones and sales-based payments.
CAR-T therapy is an advanced treatment that uses patients' genetically-engineered immune cells to fight cancer.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
March 01, 2019 04:08 ET (09:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Maxcyte Chart |
1 Month Maxcyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
